Register your Account

Sign Up with us and Enjoy!
User name Email First Name Last Name Contact info

A password will be e-mailed to you.

Biotech Stock Movers (PPHM, PFE, MRK, ESRX, WLP)

NEW YORK, September 11, 2012 (MESHPRESS) –, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares fell 3.56% and closed at $4.34 in the previous trading session. The company announced that interim results from its Phase IIb trial in patients with refractory non-small cell lung cancer showed a statistically significant improvement in overall survival and a doubling of median overall survival in the bavituximab-containing arms, compared to the control arm.

Additionally, Roth Capital restated their buy rating on shares of PPHM and the firm currently has a $5.00 price target on the stock.

Can PPHM Extend Massive Gain? Find Out Here

Pfizer Inc.(NYSE:PFE) shares fell 0.58% and closed at $24.10 in the previous trading session. Mylan Inc announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties’ patent litigation in connection with Mylan Pharmaceuticals’ Abbreviated New Drug 66698/Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer’s Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary and frequency.

Can PFE Extend Gain? Find Out Here

Merck & Co., Inc.(NYSE:MRK) shares jumped 0.48% and closed at $44.26 in the last trading session after the company priced a $2.5 billion public offering of senior unsecured notes. The notes include: $1.0 billion of 1.100% notes due 2018; $1.0 billion of 2.400% notes due 2022; and $500.0 million of 3.600% notes due 2042 Proceeds from the notes will be used for general corporate purposes, including without limitation making contributions to its pension plans and repayment of outstanding commercial paper borrowings and upcoming debt maturities. The offering is expected to close on Sept. 13, 2012.

How Should Investors Trade MRK Now? Find Out Here

Express Scripts Holding Company(NASDAQ:ESRX) shares declined 2.45% and closed at $61.75 in the previous trading session. The shares of ESRX had its “buy” rating reiterated by investment analysts at SunTrust and they currently have a $72.00 target price on the stock. Additionally, analysts expect that Express Scripts will post $3.69 EPS for the current fiscal year.

Can ESRX Jump Again? Find Out Here

WellPoint, Inc.(NYSE:WLP) shares decreased 1.39% and closed at $59.45 in yesterday’s session. Zacks reiterated their neutral rating on shares of WellPoint and the firm currently has a $63.00 price target on the stock.

Additionally, officers of WellPoint are expected to speak with securities analysts and investors during the period commencing on September 10, 2012 and ending on September 21, 2012. During these meetings, the officers expect to reaffirm WellPoint’s net income guidance for full year 2012 to be in the range of $7.30 to $7.40 per share.

Get Free Trend Analysis on To Know More About WLP Here

About has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.




Related Press realease: